Based on them, currently available retrospective data sufficiently validate the use of the circulating pretreatment MMP-7 level as an independent prognostic factor in urothelial carcinoma, and therefore no further retrospective studies are needed. This evidence concerns the gene MMP7 and urothelial carcinoma.